CCR8 expectations
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
GSK’s $625m TIGIT bet approaches crunch time
Readout of the delayed Galaxies Lung-201 study is due imminently.
FibroGen hopes to buck its pamrevlumab trend
Two pancreatic cancer trials will read out this quarter, but after a string of failures with the project they look like a long shot.
Astra goes early in small cell
The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.
The month ahead: April’s upcoming events
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
